Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
DermTech, Inc.:
We consent to the use of our report dated April 22, 2019, except for the reverse stock split described in Note 9, which is as of August 29, 2019, with respect to the balance sheets of DermTech, Inc. as of December 31, 2018 and 2017, and the related statements of operations and comprehensive loss, convertible preferred stock and stockholders’ (deficit) equity, and cash flows for each of the yearsin the two-year period ended December 31, 2018, and the related notes (collectively, the “financial statements”), incorporated herein by reference. Our report dated April 22, 2019 contains an explanatory paragraph that states that the Company has suffered recurring losses from operations and has a net capital deficiency, which raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of that uncertainty.
| /s/ KPMG LLP |
| San Diego, California |
| January 17, 2020 |